Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study.

@article{Rosenstock2006EffectOE,
  title={Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study.},
  author={Julio Rosenstock and Barry J. Goldstein and Arthur I. Vinik and Matthew C O'Neill and Lisa E Porter and Mark A Heise and Barbara G. Kravitz and Riad G Dirani and Martin I. Freed},
  journal={Diabetes, obesity & metabolism},
  year={2006},
  volume={8 1},
  pages={49-57}
}
AIM To compare the efficacy, safety and tolerability of adding rosiglitazone (RSG) vs. sulphonylurea (SU) dose escalation in older type 2 diabetes mellitus (T2DM) patients inadequately controlled on SU therapy. METHODS A total of 227 T2DM patients from 48 centres in the USA and Canada, aged > or =60 years, were randomized to receive RSG (4 mg) or placebo once daily in combination with glipizide 10 mg twice daily for 2 years in a double-blind, parallel-group study. Previous SU monotherapy was… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 19 references

Questionnaire (DTSQ)

  • C Bradley, ed
  • Obesity and Metabolism,
  • 2006

Long-term effect of rosiglitazone on pancreatic b-cell function and insulin resistance in older type-2 diabetes mellitus (T2DM) patients treated with sulfonylurea

  • A Vinik, D Yu, LJ. Strow
  • Diabetes
  • 2004

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

  • DR Matthews, JP Hosker, AS Rudenski
  • Diabetes Care
  • 2003

Similar Papers

Loading similar papers…